A NEW GENERATION OF IMMUNOTHERAPIES
AyuVis Research, Inc. is developing a new generation of immunotherapy that, rather than simply activating or suppressing the immune response, provide a
well-balanced outcome where both mild activation and controlled suppression of the immune system is needed to effectively treat disease. This process allows us to control both inflammation and infection.
NEWS & EVENTS
Keep up with the latest business and scientific progress
Seth Bodine - Fort Worth Report
Kevin Cummings -Dallas Innovates
Our Pipeline
Our lead candidate AVR-48 has been granted Orphan Drug* and Rare Pediatric Disease Designations by the US FDA** for the prevention of BPD in at-risk infants.
-
Easy to manufacture.
-
Simple to formulate.
-
Safe with no toxicity in humans.
Unlike previous generations of immunotherapy, AyuVis' compounds target the white blood cells in the innate immune system to provide a rapid response
Based on pharmacoeconomic analysis, the market potential for our lead compound AVR-48 in lung diseases is annually over $16B in the US and $35B globally
